SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Covetrus, Inc. CVET NASDAQ

NASDAQ Global Select • Healthcare • Medical - Distribution • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Covetrus, Inc. (CVET) is a Medical - Distribution company in the Healthcare sector, currently trading at $20.99. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $4.6B, +6.6%/yr average growth. Net income is $86M (loss), growing at -454.9%/yr. Net profit margin is -1.9% (negative). Gross margin is 18.8% (+0.7 pp trend).

Balance sheet: total debt is $1.0B against $1.5B equity (Debt-to-Equity (D/E) ratio 0.69, moderate). Current ratio is 1.94 (strong liquidity). Debt-to-assets is 30.7%. Total assets: $3.4B.

Analyst outlook: 0 / 1 analysts rate CVET as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 40/100 (Partial), Past 25/100 (Fail), Health 50/100 (Partial), Moat 30/100 (Fail), Future 20/100 (Fail), Income 10/100 (Fail).

CVET SharesGrow Score Overview

29/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 40/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 30/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CVET

No analyst coverage available for this stock.

CVET: +6.6%/yr revenue is, -454.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

CVET: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet CVET: Debt-to-Equity (D/E) ratio 0.69 (moderate), Current ratio is 1.94 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

CVET: Gross margin is 18.8% (+0.7 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 30/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 1 analysts rate CVET as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

CVET: Net profit margin is -1.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range13.39-21.2

Volume5.3M

Avg Volume (30D)1.22M

Beta (1Y)1.51

Share Statistics

EPS (TTM)-0.63

Shares Outstanding$137M

IPO Date2019-02-04

Employees4,035

CEOBenjamin Wolin

Financial Highlights & Ratios

Revenue (TTM)$4.58B

Gross Profit$858M

EBITDA$178M

Net Income$-86M

Operating Income$-22M

Total Cash$183M

Total Debt$1.05B

Net Debt$863M

Total Assets$3.41B

Price / Earnings (P/E)-33.3

Analyst Forecast

Rating ConsensusHold

Analysts Covering1

Buy 0% Hold 100% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Global Select

CurrencyUSD

ISINUS22304C1009

Price Chart

CVET

Covetrus, Inc. ↗ · NASDAQ Global Select

Healthcare • Medical - Distribution

13.39 52WK RANGE 21.20

People Also View

Eli Lilly and Company

Johnson & Johnson

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message